Local recurrence with and without a tumour-bed boost: A post-hoc analysis of the DBCG IMN2 study
Our results suggest that node-positive patients 50 years or older with an ER-/HER2- tumour may obtain a clinically relevant benefit from a TBB.
Authors
- Demet Özcan (ORCID: https://orcid.org/0000-0001-6537-0035)
- Birgitte Vrou Offersen (ORCID: https://orcid.org/0000-0001-7356-2096)
- Else Maae
- Trine Tramm (ORCID: https://orcid.org/0000-0003-3894-4552)
- Anders W. Mølby Nielsen (ORCID: https://orcid.org/0000-0003-2843-2879)
- Jens Overgaard (ORCID: https://orcid.org/0000-0002-0814-8179)
- Lise Bech Jellesmark Thorsen (ORCID: https://orcid.org/0000-0002-4533-1642)
- Louise W. Matthiessen
- Marie Louise Holm Milo
- Mette Holck Nielsen
Institutions
- Aalborg University Hospital (DK)
- Odense University Hospital (DK)
- Aarhus University Hospital (DK)
- Gentofte Hospital (DK)
- Vejle Sygehus (DK)
- Aalborg University (DK)
Publication Details
- Journal
- Radiotherapy and Oncology
- Published
- 2025-05-04
- DOI
- https://doi.org/10.1016/j.radonc.2025.110905
- Citations
- 4
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 3.75
Funders
- Aarhus Universitet
- Kræftens Bekæmpelse
- Institut for Klinisk Medicin, Aarhus Universitet